Herbst RS, Wu Y-L, John T et al (2023) Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol 41:1830–1840. https://doi.org/10.1200/JCO.22.02186

Article  PubMed  PubMed Central  Google Scholar 

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA et al (2016) TP53 mutation spectrum in smokers and never smoking lung cancer patients. Front Genet 7:85. https://doi.org/10.3389/fgene.2016.00085

Article  PubMed  PubMed Central  Google Scholar 

Canale M, Petracci E, Delmonte A et al (2020) Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs. J Clin Med 9:1047. https://doi.org/10.3390/jcm9041047

Article  PubMed  PubMed Central  Google Scholar 

Canale M, Petracci E, Delmonte A et al (2017) Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res 23:2195–2202. https://doi.org/10.1158/1078-0432.CCR-16-0966

Article  PubMed  Google Scholar 

Montpréville VT, L L ER (2020) Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: a clinicopathological study of 26 cases. Ann Diagn Pathol 46. https://doi.org/10.1016/j.anndiagpath.2020.151522

Qiu X, Wang Y, Liu F et al (2021) Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Am J Cancer Res 11:3189–3200

PubMed  PubMed Central  Google Scholar 

Nicholson AG, Tsao MS, Beasley MB et al (2022) The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol 17:362–387. https://doi.org/10.1016/j.jtho.2021.11.003

Article  PubMed  Google Scholar 

Ilie M, Khambata-Ford S, Copie-Bergman C (2017) Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS One 12:e0183023. https://doi.org/10.1371/journal.pone.0183023

Article  PubMed  PubMed Central  Google Scholar 

Ilié M, Hofman V, Bontoux C et al (2022) Setting up an ultra-fast next-generation sequencing approach as reflex testing at diagnosis of non-squamous non-small cell lung cancer; experience of a single center (LPCE, Nice, France). Cancers (Basel) 14:2258. https://doi.org/10.3390/cancers14092258

Article  PubMed  Google Scholar 

Lassalle S, Hofman V, Heeke S (2020) Targeted assessment of the EGFR status as reflex testing in treatment-naive non-squamous cell lung carcinoma patients: a single laboratory experience. Cancers (Basel) 12:955

Article  PubMed  Google Scholar 

Alcazer V (2020) StatAid: an R package with a graphical user interface for data analysis. JOSS 5:2630. https://doi.org/10.21105/joss.02630

Article  Google Scholar 

Liu D-H, Zhao Z-R, Lin Y-B et al (2019) Prognostic effect of TP53 and PKD Co-mutations in patients with resected epidermal growth factor receptor-mutated lung adenocarcinoma. Ann Surg Oncol 26:1934–1941. https://doi.org/10.1245/s10434-019-07254-6

Article  PubMed  Google Scholar 

Molina-Vila MA, Bertran-Alamillo J, Gascó A et al (2014) Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res 20:4647–4659. https://doi.org/10.1158/1078-0432.ccr-13-2391

Article  PubMed  Google Scholar 

Roeper J, Falk M, Chalaris-Rißmann A et al (2020) TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: a strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Oncotarget 11:250–264. https://doi.org/10.18632/oncotarget.27430

Article  PubMed  PubMed Central  Google Scholar 

Michels S, Heydt C, van Veggel B et al (2019) Genomic profiling identifies outcome-relevant mechanisms of innate and acquired resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor therapy in lung cancer. JCO Precis Oncol 3:PO.18.00210. https://doi.org/10.1200/PO.18.00210

Article  PubMed  PubMed Central  Google Scholar 

Hondelink LM, Ernst SM, Atmodimedjo P et al (2023) Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. Eur J Cancer 181:53–61. https://doi.org/10.1016/j.ejca.2022.12.010

Article  PubMed  Google Scholar 

Zhou W, Liu Z, Wang Y et al (2022) The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma. Cancer Med 11:1299–1309. https://doi.org/10.1002/cam4.4543

Article  PubMed  PubMed Central  Google Scholar 

Ma PC, Kijima T, Maulik G et al (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272–6281

PubMed  Google Scholar 

Choong W-K, Sung T-Y (2021) Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities. iScience 24:102522. https://doi.org/10.1016/j.isci.2021.102522

Article  PubMed  PubMed Central  Google Scholar 

Saw SPL, Ng WP, Zhou S et al (2023) PD-L1 score as a prognostic biomarker in Asian early-stage epidermal growth factor receptor-mutated lung cancer. Eur J Cancer 178:139–149. https://doi.org/10.1016/j.ejca.2022.10.012

Article  PubMed  Google Scholar 

Jung HA, Lim J, Choi Y-L et al (2022) Clinical, pathologic, and molecular prognostic factors in patients with early-stage EGFR-mutant NSCLC. Clin Cancer Res 28:4312–4321. https://doi.org/10.1158/1078-0432.CCR-22-0879

Article  PubMed  Google Scholar 

Yang Z, Chen Y, Wang Y et al (2021) Efficacy of EGFR-TKI plus chemotherapy or monotherapy as first-line treatment for advanced EGFR-mutant lung adenocarcinoma patients with co-mutations. Front Oncol 11:681429. https://doi.org/10.3389/fonc.2021.681429

Article  PubMed  PubMed Central  Google Scholar 

Yamamoto N, Seto T, Nishio M et al (2021) Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study. Lung Cancer 151:20–24. https://doi.org/10.1016/j.lungcan.2020.11.020

Article  PubMed  Google Scholar 

Villaruz LC, Wang X, Bertino EM et al (2023) A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. ESMO Open 8:101183. https://doi.org/10.1016/j.esmoop.2023.101183

Article  PubMed  PubMed Central  Google Scholar 

Aggarwal C, Bubendorf L, Cooper WA et al (2021) Molecular testing in stage I-III non-small cell lung cancer: approaches and challenges. Lung Cancer 162:42–53. https://doi.org/10.1016/j.lungcan.2021.09.003

Article  PubMed  Google Scholar 

Hofman P, Calabrese F, Kern I et al (2023) Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 8. https://doi.org/10.1016/j.esmoop.2023.101628

Anand K, Phung TL, Bernicker EH et al (2020) Clinical utility of reflex ordered testing for molecular biomarkers in lung adenocarcinoma. Clin Lung Cancer 21:437–442. https://doi.org/10.1016/j.cllc.2020.05.007

Article  PubMed  Google Scholar 

Canale M, Andrikou K, Priano I et al (2022) The role of TP53 mutations in EGFR-mutated non-small-cell lung cancer: clinical significance and implications for therapy. Cancers (Basel) 14:1143. https://doi.org/10.3390/cancers14051143

Article  PubMed  PubMed Central  Google Scholar 

Fu J, Tong Y, Xu Z et al (2023) Impact of TP53 mutations on EGFR-tyrosine kinase inhibitor efficacy and potential treatment strategy. Clin Lung Cancer 24:29–39. https://doi.org/10.1016/j.cllc.2022.08.007

Article  PubMed  Google Scholar 

Qin K, Hou H, Liang Y, Zhang X (2020) Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer 20:328. https://doi.org/10.1186/s12885-020-06805-5

Article  PubMed  PubMed Central  Google Scholar 

Lan B, Zhao N, Du K, Leng B (2022) Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: an updated systematic review and meta-analysis. Oncol Lett 24:384. https://doi.org/10.3892/ol.2022.13504

Article  PubMed  PubMed Central  Google Scholar 

Hellyer JA, White MN, Gardner RM et al (2022) Impact of tumor suppressor gene co-mutations on differential response to EGFR TKI therapy in EGFR L858R and exon 19 deletion lung cancer. Clin Lung Cancer 23:264–272. https://doi.org/10.1016/j.cllc.2021.09.004